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In modern molecular genetics, epistasis
analysis is a tool for probing the relation-
ship between two genes and, hence,
between the two genes’ products. In its
broadest sense, an epistatic relationship
exists when combinations of specific alleles
of two or more genes generate a quanti-
tative phenotype that differs from the
simple addition of phenotypes associated
with each individual allele. Many different
types of gene–gene interaction could be
characterized as epistatic. In its purest
form, an allele a of gene A is said to be
epistatic to (literally, ‘‘standing over’’)
allele b of gene B if both a and b
individually confer a quantitative defect
in a particular phenotype, the defect
caused by a is more severe than b, and
the phenotype of ab resembles that of a.I n
this case, the presence of allele b is
irrelevant if allele a is present. Clear-cut
genetic interactions of this type might
indicate that there is an equally clear-cut
biochemical interaction between the gene
products, A and B. In the example
outlined above, A might act on the same
biochemical pathway as B and effectively
control its activities.
Epistasis analysis has provided useful
insights into the quite complex gene
relationships that constitute the BRCA1/
BRCA2 pathway of homologous recombi-
nation (HR). In the early days of work on
BRCA1 and BRCA2, as their roles in HR
were beginning to come into focus, several
studies indicated that Brca null mice die in
utero around E7.5 (Brca1
2/2) or E8.5
(Brca2
2/2). The two phenotypes were
similar—cell cycle arrest accompanied by
p53activationanda chromosome breakage
pattern with a predominance of chromatid-
type aberrations. Ludwig et al. attempted
an epistasis analysis of BRCA1 and BRCA2
mutation in the mouse and observed three
Brca1
2/2Brca2
2/2 embryos that died
,E7.5 [1]. Although the statistical power
of thisexperiment was low, itsuggested that
Brca1
2/2 might be epistatic to Brca2
2/2
and appeared to support the idea that
BRCA1 and BRCA2 operate on a com-
mon biochemical pathway connected with
organismal viability. More than a decade
later, it is clear that that conclusion was
basically correct; however, many interest-
ing and important distinctions between the
two genes have also come to light. Notably,
the lethal phenotype of BRCA1 null mice is
largely suppressed by deletion of 53BP1
[2,3].
Differences between BRCA1 and
BRCA2 have also emerged from studies
of their molecular function. BRCA2
associates stoichiometrically with Rad51
and has a key role in loading Rad51 onto
single-stranded DNA that is created by
double-strand break (DSB) resection, as a
prelude to Rad51-mediated strand ex-
change. In contrast, BRCA1 functions in
earlier steps of DSB repair, both by
controlling DSB resection and by facilitat-
ing the transition from DSB resection to
BRCA2-mediated Rad51 loading via
BRCA1’s and BRCA2’s mutual interac-
tions with PALB2/FANCN. BRCA1 par-
ticipates in multiple distinct protein com-
plexes, some of which function on
chromatin and may regulate transcription.
In the clinical setting, BRCA1-linked
breast cancers are more often of the ‘‘triple
negative’’ basal type than are either
sporadic or BRCA2-linked breast cancers,
for reasons that are not well understood.
Very likely, breast/ovarian cancer risk and
the responsiveness of BRCA-linked cancers
to poly(ADP) ribose polymerase (PARP)
inhibitors are reflections of HR functions
shared by BRCA1 and BRCA2. The
additional phenotypic ‘‘overlay’’ associat-
ed with BRCA1-linked cancers may reflect
the impact of perturbing BRCA1 functions
that are not shared with BRCA2.
Despite this progress in understanding
the functions of BRCA1 and BRCA2, little
epistasis data regarding their relationship
has been reported since the work of
Ludwig et al. In this issue of PLoS Genetics,
Qing et al. have used the genetically
tractable chicken lymphoblastoid cell line
DT40 to undertake such an analysis,
focusing on BRCA2 [4]. Their work sheds
important light on the functional relation-
ships between BRCA1, BRCA2, Rad51,
and other HR mediators. First, by gener-
ating a (probable) null allele of BRCA2,
they show that complete or near-complete
loss of BRCA2 function is compatible with
cell viability, in dramatic contrast to the
Rad51 null phenotype, which is cell lethal
in DT40 [5]. Thus, although BRCA2
loads Rad51 protein, Rad51 must have cell
viability functions that are independent of
BRCA2. Combined deletion of BRCA1 and
BRCA2 produced no additive impairment
of cell growth. However, when the authors
studied the impact of combined BRCA1
and BRCA2 mutations on sensitivity to
DNA damaging agents, a more complex
and nuanced picture emerged. In response
to cis-platin, an agent that induces inter-
strand DNA cross-links and engages HR
as an essential part of their repair, or to the
PARP inhibitor olaparib, BRCA2 null
mutation appears to be epistatic to all
HR mediator mutants the authors tested,
including BRCA1. However, in the re-
sponse to camptothecin, a topoisomerase I
poison that induces DSBs at replication
forks, the pattern was quite different.
BRCA1 null cells were found to be much
more sensitive to camptothecin than
BRCA2 null cells and, surprisingly, the
combined mutation produced an interme-
diate phenotype. Thus, loss of BRCA2
partially ameliorates the BRCA1 null
hypersensitivity to camptothecin. This
deviation from simple epistasis is impor-
tant and not yet explained, but a reason-
able starting assumption is that the
different DNA structures generated by
the three DNA damaging agents tested
call to a different extent upon specific and
distinct DNA repair functions of BRCA1
and BRCA2. In this regard, a gene might
appear to be a ‘‘master regulator’’ of its
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servant’’ in another.
Understanding the extent to which
these complex genetic interactions are
played out in tumorigenesis and in the
response to different cancer therapies is an
important goal of translational research.
We should expect more surprises and
insights to emerge from epistasis analysis
of BRCA-linked cancer and cancer therapy
in animal models.
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